Literature DB >> 17410413

Immunohistochemical properties of silent corticotroph adenoma and Cushing's disease.

Kazumi Iino1, Yutaka Oki, Fumie Matsushita, Miho Yamashita, Chiga Hayashi, Katsutoshi Miura, Shigeru Nishizawa, Hirotoshi Nakamura.   

Abstract

Proopiomelanocortin processing in corticotroph cells is known to be operated by prohormone convertase (PC) 1/3 which is activating several pro-proteins and prohormones by intracellular limited proteolysis processing. In this study, we hypothesized that PC1/3 expression differs between Cushing's disease (CD) and silent corticotroph adenoma (SCA), and investigated whether PC1/3 expression is involved in the adrenocorticotropin (ACTH) silence of SCA. We performed immunohistochemical analysis of pituitary adenoma specimens for six adenohypophysial hormones, PC1/3 and chromogranin A (CgA). Subjects for this study consisted of 12 anterior pituitary adenomas of CD (1 male, 11 female; 14-70 years old) and 31 non-functioning adenomas (23 male, 8 female; 32-71 years old).ACTH immunoreactivity was observed in all of CD and three of 31 non-functioning adenomas. The three cases diagnosed as SCA were also positive for growth hormone and follicle-stimulating hormone. Cushing's adenomas and SCAs were all positive for PC1/3. PC1/3-positive cells did not always colocalize with ACTH but some of them colocalized with CgA in SCAs. Even if PC1/3 is not present in corticotroph cells, PC1/3 immunoreactivity in SCA may originate from CgA-positive cells. We conclude that immunohistochemistry for PC1/3 is not helpful for differential diagnosis between CD and SCA in clinical practice, though the regulation of PC1/3 expression is likely to be an important etiological factor in ACTH silence of SCA. The diversity of immunohistochemical properties of SCA leads us to speculate that it is not a single entity and may be a general diagnostic term for adenomas of varying etiology.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17410413     DOI: 10.1007/s11102-007-0010-5

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  33 in total

1.  Metamorphosis of a non-functioning pituitary adenoma to Cushing's disease.

Authors:  B Ambrosi; L Barbetta; C Dall'Asta; R Libé
Journal:  Pituitary       Date:  2001-08       Impact factor: 4.107

2.  Clinically silent corticotroph tumors of the pituitary gland.

Authors:  B W Scheithauer; A J Jaap; E Horvath; K Kovacs; R V Lloyd; F B Meyer; E R Laws; W F Young
Journal:  Neurosurgery       Date:  2000-09       Impact factor: 4.654

3.  Metamorphosis of a non-functioning pituitary adenoma to Cushing's disease.

Authors:  E U Tan; M S Ho; C R Rajasoorya
Journal:  Pituitary       Date:  2000-10       Impact factor: 4.107

4.  Immunohistochemical evaluation of the post-translational processing of chromogranin A in human pituitary adenomas.

Authors:  A P Heaney; W J Curry; K M Pogue; V L Armstrong; M Mirakhur; B Sheridan; C F Johnston; K D Buchanan; A B Atkinson
Journal:  Pituitary       Date:  2000-10       Impact factor: 4.107

5.  Pro-opiomelanocortin gene expression in silent corticotroph-cell adenoma and Cushing's disease.

Authors:  T Nagaya; H Seo; A Kuwayama; T Sakurai; N Tsukamoto; T Nakane; K Sugita; N Matsui
Journal:  J Neurosurg       Date:  1990-02       Impact factor: 5.115

6.  Localization of prohormone convertases 1/3 and 2 in the human pituitary gland and pituitary adenomas: analysis by immunohistochemistry, immunoelectron microscopy, and laser scanning microscopy.

Authors:  I Takumi; D F Steiner; N Sanno; A Teramoto; R Y Osamura
Journal:  Mod Pathol       Date:  1998-03       Impact factor: 7.842

7.  In situ hybridization study of pro-opiomelanocortin (POMC) gene expression in human pituitary corticotrophs and their adenomas.

Authors:  L Stefaneanu; K Kovacs; E Horvath; R V Lloyd
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

8.  Secretion of high-molecular-weight adrenocorticotropic hormone from a pituitary adenoma in a patient without Cushing stigmata. Case report.

Authors:  Akira Matsuno; Ryo Okazaki; Yutaka Oki; Tadashi Nagashima
Journal:  J Neurosurg       Date:  2004-11       Impact factor: 5.115

Review 9.  Biosynthesis of peptide hormones derived from precursor sequences.

Authors:  R von Eggelkraut-Gottanka; A G Beck-Sickinger
Journal:  Curr Med Chem       Date:  2004-10       Impact factor: 4.530

10.  Composite somatotroph--ACTH-immunoreactive pituitary adenoma with transformation of hyperplasia to adenoma.

Authors:  N Mazarakis; G Kontogeorgos; K Kovacs; E Horvath; N Borboli; G Piaditis
Journal:  Pituitary       Date:  2001-09       Impact factor: 4.107

View more
  3 in total

Review 1.  Predictors of silent corticotroph adenoma recurrence; a large retrospective single center study and systematic literature review.

Authors:  Fabienne Langlois; Dawn Shao Ting Lim; Chris G Yedinak; Isabelle Cetas; Shirley McCartney; Justin Cetas; Aclan Dogan; Maria Fleseriu
Journal:  Pituitary       Date:  2018-02       Impact factor: 4.107

Review 2.  Modification of hormonal secretion in clinically silent pituitary adenomas.

Authors:  Tania Daems; Johan Verhelst; Alex Michotte; Pascale Abrams; Dirk De Ridder; Roger Abs
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

Review 3.  An Update on Silent Corticotroph Adenomas: Diagnosis, Mechanisms, Clinical Features, and Management.

Authors:  Shenzhong Jiang; Xiaokun Chen; Yinzi Wu; Renzhi Wang; Xinjie Bao
Journal:  Cancers (Basel)       Date:  2021-12-06       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.